ClinicalTrials.gg
Active, not recruitingNCT05653219VAYHIT2Updated Nov 9, 2026

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

A Phase 3 interventional study of Ianalumab and Eltrombopag in Primary Immune Thrombocytopenia, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 74 sites in 24 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Nov 9, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.

Enrollment
4th of 12
152 · median 39
Started
2023
with 2 others
Phase 3
4 of 17
none open now
Registered
8th of 17
by date

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 3, and was the 8th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.

Read the detailed description

This is a multicenter, randomized, double-blinded phase 3 study to assess efficacy and safety of two different doses of ianalumab versus placebo in addition to eltrombopag in adults with primary ITP (platelet count \<30 G/L) who failed previous first-line treatment with corticosteroids.

After completion of the screening period, the participants will enter the randomized treatment period (ianalumab/placebo with eltrombopag) followed by the eltrombopag tapering period. Afterwards, all participants will enter the follow-up period to be monitored for efficacy and safety or safety only depending on how the participants responded to the study treatment.

03

Conditions studied

  • Primary Immune Thrombocytopenia

Keywords

  • Primary immune thrombocytopenia (ITP),
  • ianalumab
  • VAY736
  • B-cell depletion
  • B-cell Activating Factor Receptor (BAFF-R) blockade
  • eltrombopag
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria

  1. Male or female patients aged 18 years and older on the day of signing the .
  2. A signed informed consent must be obtained prior to participation in the study.
  3. A diagnosis of primary ITP, with insufficient response to, or relapse after a therapy ± IVIG.
  4. Patient with count \<30G/L (whom eltrombopag is clinically indicated as per physician's discretion) and with no to receive eltrombopag

Key Exclusion criteria

  1. ITP patients who received second-line ITP treatments (other than steroid therapy± IVIG) including splenectomy. However, patients exposed to thrombopoietin receptor agonists (TPO-RAs) for a limited time (max one week) before screening are eligible.
  2. Patients with key lab abnormalities and patients with Evans syndrome or any other cytopenia, (patients with low grade anemia related to bleeding or iron deficiency are eligible).
  3. Patients with history of hematological disorders, or with marked altered hematologic parameters
  4. Patients with current or history of life-threatening bleeding
  5. Patient that are (HIV), Virus (HCV), surface Antigen (HBsAg)/ Hepatitis B core antibody (HBcAb)-positive. HBcAb-positive patients can be enrolled if HBsAg negative, HBV DNA negative, no pre-existing liver fibrosis is present and antiviral prophylaxis is given
  6. Patients with known active or uncontrolled infection requiring systemic treatment during screening period
  7. Patients with hepatic impairment
  8. Patients with concurrent coagulation disorders and/or receiving antiplatelet or anticoagulant medication with an exemption of low dose of acetylsalicylic acid (≤150 mg daily)
  9. Nursing (breast feeding) or pregnant women

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Treatment arm 1 - Lower dose

    Participants will receive eltrombopag and ianalumab lower dose

    Biological: Ianalumab · Drug: Eltrombopag

  • Experimental
    Treatment arm 2 - Higher dose

    Participants will receive eltrombopag and ianalumab higher dose

    Biological: Ianalumab · Drug: Eltrombopag

  • Placebo comparator
    Treatment arm 3 - Placebo

    Participants will receive eltrombopag and placebo

    Drug: Eltrombopag · Drug: Placebo

Interventions

  • BiologicalIanalumab

    Concentrate for solution for infusion for intravenous use

    Also known as: VAY736

  • Film-coated tablet for oral use

    Also known as: ETB115

  • DrugPlacebo

    Concentrate for solution for infusion for intravenous use.

06

What researchers measure

Primary outcomes

  1. Time from randomization until treatment failure

    Time from randomization until treatment failure is defined as the time from randomization date until the first of the following events indicative of treatment failure: * platelet count below 30 G/L * start of a new ITP treatment * need for a rescue treatment * ineligibility to taper or inability to discontinue eltrombopag * death

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

Secondary outcomes

  1. Stable response at 6 months (Key Secondary Endpoint)

    Percentage of participants with at least 3 platelet count collected at month 6 (between study days 121 and 183 and at least 75% of platelet counts qualified as a response).

    Time frame: At 6 months

  2. Complete Response rate at each timepoint

    Percentage of participants with any platelet count of at least 100 G/L in the absence of rescue treatment or new ITP treatment

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  3. Response rate at each timepoint

    Percentage of participants with any platelet count of at least 50 G/L in the absence of rescue treatment or new ITP treatment

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  4. Best response rate across all timepoints

    Percentage of participants with a best response rate of either response or complete response

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  5. Time to first response/time to first complete response

    Time from randomization to date of first response and time from randomization to date of first complete response

    Time frame: Time from randomization up to the longest observed treatment period duration

  6. Duration of response

    Time from achievement of response to treatment failure.

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  7. Stable response at 1 year

    Percentage of participants with at least 2 platelet count collected at year 1 (between study days 296 and 379 and at least 66% of platelet counts qualified as a response).

    Time frame: At 1 year

  8. Duration of complete response

    Time from achievement of complete response to loss of complete response stable response at 1 year period

    Time frame: Randomization to end of study (up to 39 months after randomization of last participant)

  9. Rate of participants who successfully taper and discontinue eltrombopag in each treatment arm

    Probability to be treatment failure-free (as defined for the primary efficacy endpoint)

    Time frame: up to week 24

  10. Percentage of participants with bleeding events according to World Health Organization (WHO)

    Percentage of participants reporting bleeding events according to WHO bleeding scale

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  11. Number of participants receiving rescue treatment

    Number of participants who are in need of rescue treatment in each treatment arm

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  12. Percentage of participants receiving rescue treatment

    Percentage of participants who are in need of rescue treatment

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  13. Change from baseline in the frequency of CD19+ B-cell counts

    Post-baseline frequency of CD19+ B-cell counts (percentage within CD45) compared to baseline

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  14. Change from baseline in the absolute number of CD19+ B-cell counts

    Post-baseline absolute number of CD19+ B-cell counts compared to baseline

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  15. Change from baseline on T-score of the PROMIS SF v1.0 Fatigue 13a

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Fatigue 13a includes 13 items that assess fatigue in adults.

    Time frame: From screening (baseline) until end of study (up 39 months after randomization of last participant)

  16. Change from baseline in ITP PAQ domain scores of symptoms, fatigue, bother (uncomfortable), activity

    The ITP-PAQ is a 44 item scale for measuring HRQoL in adults with ITP across ten scales: Symptoms, Bother-Physical Health, Fatigue/Sleep, Activity, Fear, Psychological Health, Work, Social Activity, Women´s Reproductive Health, overall QoL. Each item is rated on a Likert type scale. Each scale is scored from 0 to 100. Higher scores represent better HRQoL.

    Time frame: From screening (baseline) until end of study (up 39 months after randomization of last participant)

  17. Time to first occurence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL

    Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  18. Change from baseline in immunoglobulins

    Change from baseline in immunoglobulin levels

    Time frame: Randomization to until end of study (up to 39 months after randomization of last participant)

  19. PK parameters: AUClast

    AUClast: Area under the curve from time zero to the last measurable concentration sampling time (tlast)

    Time frame: After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

  20. PK parameters: AUCtau

    AUCtau: Area under the curve calculated to the end of a dosing interval (tau)

    Time frame: After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

  21. PK parameters: Cmax

    Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

    Time frame: After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

  22. PK parameters: Tmax

    Time to reach maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

    Time frame: After first dose (pre-dose, EOI, 168, 336 and 504 hours post dose) and after last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

  23. PK parameters: Accumulation ratio Racc

    Accumulation ratio calculated using AUC values obtained after the last and first dose

    Time frame: After last dose (pre-dose, EOI, 336, 672, 2016, 3360 hours post dose)

  24. Incidence of anti-ianalumab antibodies in serum (ADA assay) over time

    Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assessing the immunogenicity of ianalumab

    Time frame: up to week 33

  25. Titer of anti-ianalumab antibodies in serum (ADA assay) over time

    Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assessing the immunogenicity of ianalumab

    Time frame: up to week 33

07

Study locations

74 sites
  • Yuma Regional Medical Center
    Yuma, Arizona 85364, United States
  • University of Colorado Anschutz
    Aurora, Colorado 80045, United States
  • Endeavor Health
    Evanston, Illinois 60201, United States
  • Boston Medical Center
    Boston, Massachusetts 02215, United States
  • UMASS Memorial Medical Center
    Worcester, Massachusetts 01665, United States
  • Michigan Center of Medical Research
    Farmington Hills, Michigan 48334, United States
  • St Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • Hematology Oncology Association of Rockland
    Nyack, New York 10960, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Yvoir, Namur 5530, Belgium
  • Novartis Investigative Site
    Roeselare, West Vlaanderen 8800, Belgium
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Binzhou, Shandong 256603, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Tianjin, 300020, China
  • Novartis Investigative Site
    Brno, 625 00, Czechia
  • Novartis Investigative Site
    Prague, 100 34, Czechia
  • Novartis Investigative Site
    Prague, 128 08, Czechia
  • Novartis Investigative Site
    Blois, 41000, France
  • Novartis Investigative Site
    Le Mans, 72000, France
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Rishikesh, Uttarakhand 249203, India
  • Novartis Investigative Site
    Kolkata, West Bengal 700014, India
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Roma, RM 00133, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Trieste, TS 34129, Italy
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4538511, Japan
  • Novartis Investigative Site
    Osaka, Osaka 5400006, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Kofu, Yamanashi 4008506, Japan
  • Novartis Investigative Site
    Kumamoto, 8600008, Japan
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88586, Malaysia
  • Novartis Investigative Site
    Subang Jaya, Selangor 47500, Malaysia
  • Novartis Investigative Site
    George Town, 10050, Malaysia
  • Novartis Investigative Site
    Johor Bahru, 80100, Malaysia
  • Novartis Investigative Site
    Kuala Selangor, 68000, Malaysia
  • Novartis Investigative Site
    Saltillo, Coahuila 25230, Mexico
  • Novartis Investigative Site
    Morelia, Michoacán 58260, Mexico
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Leiden, South Holland 2333 ZA, Netherlands
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
  • Novartis Investigative Site
    Makati City, 1229, Philippines
  • Novartis Investigative Site
    Quezon, 1102, Philippines
  • Novartis Investigative Site
    Craiova, Dolj 200136, Romania
  • Novartis Investigative Site
    Timișoara, 300079, Romania
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Jeollanam, 519763, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Salamanca, 37007, Spain
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Samsun, Atakum 55200, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Bilkent Cankaya 06800, Turkey (Türkiye)
  • Novartis Investigative Site
    Aydin, Efeler 09100, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, Fatih 34098, Turkey (Türkiye)
  • Novartis Investigative Site
    Izmir, 35100, Turkey (Türkiye)
  • Novartis Investigative Site
    London, E1 1BB, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 7LE, United Kingdom
08

References and documents

Publications

  • Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, Urban P, Fronczek J, Foster M, Weill M, Zhang L, Hou M, Zander T, Sharif A, Sun J, Nath UK, Schutgens R, Rossi E, Deleu L, Cervinek L, Yoon JH, Chang H, Ruchutrakool T, Iino M, Goto T, Zaja F; VAYHIT2 Investigators. Ianalumab plus Eltrombopag in Immune Thrombocytopenia. N Engl J Med. 2026 Apr 16;394(15):1503-1513. doi: 10.1056/NEJMoa2515168. Epub 2025 Dec 9. PubMed 41363800 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jun 2025, 28 months.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 28 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Dec 16, 2022
StartActual
Feb 2, 2023
Primary completionActual
Jun 19, 2025
CompletionEst.
Apr 8, 2028
Results delay requested
Jun 12, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (1 United States, 1 Belgium)
  • Endeavor Health · Evanston, United States
  • Novartis Investigative Site · Roeselare, Belgium
Show 2 removed
  • NorthShore University Health System · Evanston, United States
  • Novartis Investigative Site · Roeselare, Belgium
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 United States, 1 Belgium)
    • Endeavor Health · Evanston, United States
    • Novartis Investigative Site · Roeselare, Belgium
    Show 2 removed
    • NorthShore University Health System · Evanston, United States
    • Novartis Investigative Site · Roeselare, Belgium
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05653219
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Feb 2, 2023
Primary completion
Jun 19, 2025
Completion
Apr 8, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion